Expert Point of View: Cora N. Sternberg, MD


Get Permission

Press conference moderator Cora N. Sternberg, MD, Chief of Medical Oncology at San Camillo and Forlanini Hospitals, Rome, called the 2- to 3-month improvement in overall survival “worthwhile, and clinically meaningful.” She said this should be viewed in the context of manageable toxicity.

“Cediranib is a tyrosine kinase inhibitor that has a different mechanism of action from bevacizumab [Avastin]. I can envision using cediranib in a patient who becomes resistant to bevacizumab,” she commented.

“Cediranib is not a licensed drug, and won’t be available unless the manufacturer decides to continue with its development. With a positive study like this, AstraZeneca may rethink the situation,” she said. ■

Disclosure: Dr. Sternberg reported no potential conflicts of interest.


Related Articles

Cediranib Achieves 'Groundbreaking' Results in Relapsed Ovarian Cancer

The investigational oral vascular endothelial growth factor (VEGF) inhibitor cediranib extended progression-free survival when given with platinum-based chemotherapy and improved overall survival when given as maintenance therapy in patients with recurrent ovarian cancer. Experts are hopeful that...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.